Lavipharm S.A. Stock

LAVI

GRS246003008

Pharmaceuticals

Market Closed - Athens S.E. 17:13:55 23/10/2026 +03			5-day change	1st Jan Change
1.452 ^EUR	-1.22%		-3.71%	+49.69%

09-17	Lavipharm S.A. Reports Earnings Results for the Half Year Ended June 30, 2026	CI
06-25	Lavipharm S.A. announces Annual dividend, payable on July 24, 2026	CI

Lavipharm SA is a Greece-based pharmaceutical and healthcare company engaged in the research and development of drug delivery solutions and the commercialisation of pharmaceutical, over-the-counter (OTC) and related healthcare products. It is active in the provision of prescription medicines, OTC products and food supplements, supported by integrated activities across research and development, manufacturing and commercial operations. It maintains a portfolio focused primarily on therapeutic areas including cardiology, central nervous system disorders, urology, oncology and chronic pain, supplying solutions designed for healthcare professionals and patients. The Company operates in both domestic and international markets and combines product development capabilities with market access and distribution activities, while acting as the parent entity of the Lavipharm Group through which its broader operations are conducted.

Employees

306

Sector

Pharmaceuticals

More about the company

Quotes

Date	Price	Change	Volume
23/10/26	€1.452	-1.22%	47,951
22/10/26	€1.470	-1.87%	40,491
21/10/26	€1.498	-0.53%	103,540
20/10/26	€1.506	-0.26%	38,050
19/10/26	€1.510	+0.13%	9,207

Delayed Quote Athens S.E.

More quotes

Stock Market
Stocks
LAVI Stock

The best tools reserved for subscribers to boost the performance of your investments!

Market Cap	248M 278M 229M 208M 388M 26.36B 395M 2.76B 1.09B 13.81B 1.04B 1.02B 43.54B	P/E 2024	14.9x	P/E 2025	27.9x
Enterprise Value	275M 308M 254M 230M 430M 29.2B 437M 3.05B 1.21B 15.3B 1.15B 1.13B 48.23B	EV / Sales 2024	3.07x	EV / Sales 2025	3.04x
Free-Float	38.91%	Yield 2024	2.52%	Yield 2025	2.06%

09-17	Lavipharm S.A. Reports Earnings Results for the Half Year Ended June 30, 2026	CI
06-25	Lavipharm S.A. announces Annual dividend, payable on July 24, 2026	CI
05-28	Lavipharm Q1 earnings before tax from continuing operations EUR1.41 million, up 28.6% Y/Y	RE
05-28	Lavipharm S.A. Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
04-09	Lavipharm to acquire Durogesic pain patch rights from Janssen for $12.0 million	RE
03-19	Lavipharm SA FY 2025 earnings after tax EUR 6.0 million versus EUR 9.0 million year ago	RE
03-19	Lavipharm S.A. Reports Earnings Results for the Full Year Ended December 31, 2025	CI
11-17	Lavipharm 9-month net profit down to EUR 3.5 million	RE
18/09/25	Lavipharm H1 adjusted EBITDA at EUR 7.7 million, up 29.4% Y/Y	RE
18/09/25	Lavipharm S.A. Reports Earnings Results for the Half Year Ended June 30, 2025	CI
03/07/25	Lavipharm S.A. announces Annual dividend, payable on July 24, 2025	CI
15/05/25	Lavipharm Q1 Net Profit At EUR 1.6 Million, Up 46.8% YoY	RE
14/04/25	Lavipharm And Tikun Olam Europe Launch Joint Telemedicine Company	RE

10-01	Lavipharm S A : Announcement	PU
09-03	Lavipharm S A : Announcement Appointment of Chief Manufacturing & Operations Officer	PU
06-11	Lavipharm S A : Announcement Appointment of Chief Quality Officer	PU
05-22	Lavipharm S A : IMPORTANT CORPORATE EVENTS	PU
11-07	Lavipharm S A : OTHER ANNOUNCEMENTS	PU

1 day	-1.22%
1 week	-3.71%
Current month	-7.75%
1 month	-7.98%
3 months	+0.14%
6 months	+3.86%
Current year	+49.69%

1 week	1.43	1.53
1 month	1.43	1.59
Current year	0.94	1.74
1 year	0.78	1.74
3 years	0.6	1.74
5 years	0.35	2.22
10 years	0.21	2.22

Lavipharm S.A. Stock

Stocks

LAVI

GRS246003008

Pharmaceuticals

Valuation: Lavipharm S.A.

Chart: Lavipharm S.A.

Latest news: Lavipharm S.A.

Press Releases: Lavipharm S.A.

Quotes and Performance

Price Extremes

Managers and Directors: Lavipharm S.A.

Latest insider transactions

Generic Pharmaceuticals

Financials

Company Profile

Quotes

Manager	Title	Age	Since
Vassilis Baloumis DFI	Director of Finance/CFO	-	01/12/2021
Ligia Panaitescu CTO	Chief Tech/Sci/R&D Officer	-	-
Eleana Nikolopoulou CMP	Compliance Officer	-	-

Director	Title	Age	Since
Venetsiana-Loukia Lavida BRD	Director/Board Member	-	-
Christos Panagiotis Diamantopoulos BRD	Director/Board Member	76	-
Minas G. Tanes CHM	Chairman	86	01/01/2021

Date	Insider	Type	Main position	Quantity	% Market Cap.
2/12/25 A	Vassilis Baloumis	Buy	Chief Financial Officer	20,000	0.0119%
5/27/23 A	Thomas Tseronis	Sell		35,434	0.0189%
3/28/23 A	Vassilis Baloumis	Buy	Chief Financial Officer	23,455	0.0125%

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
LAVIPHARM S.A.	-1.22%	-3.71%	+80.37%	+135.71%	278M
ELI LILLY AND COMPANY	-2.54%	+1.31%	+54.27%	+114.96%	1,135B
JOHNSON & JOHNSON	-1.42%	+3.23%	+38.56%	+74.44%	636B
ABBVIE INC.	+0.16%	+0.08%	+25.29%	+95.23%	505B
ROCHE HOLDING AG	-0.31%	+3.09%	+44.14%	+64.80%	378B
MERCK & CO., INC.	-1.34%	-0.47%	+66.04%	+41.00%	358B
NOVARTIS AG	-0.68%	+2.65%	+22.98%	+50.39%	295B
ASTRAZENECA PLC	-1.20%	+3.04%	+2.33%	+22.86%	266B
AMGEN INC.	-1.79%	+1.57%	+50.56%	+59.08%	237B
GILEAD SCIENCES, INC.	-0.73%	-0.10%	+29.02%	+99.67%	193B
Average	-1.11%	+1.58%	+41.36%	+75.81%	400.46B
Weighted average by Cap.	-1.35%	+2.66%	+41.03%	+79.76%

	2024	2025
Net sales	52.95M 59.29M 48.91M 44.33M 82.93M 5.63B 84.3M 589M 233M 2.95B 223M 218M 9.3B	62.58M 70.08M 57.82M 52.39M 98.02M 6.65B 99.64M 696M 275M 3.49B 263M 257M 10.99B
Net income	8.98M 10.06M 8.3M 7.52M 14.07M 955M 14.3M 99.85M 39.53M 500M 37.75M 36.94M 1.58B	5.99M 6.7M 5.53M 5.01M 9.38M 636M 9.53M 66.55M 26.35M 333M 25.16M 24.62M 1.05B
Net Debt	28.34M 31.73M 26.18M 23.72M 44.38M 3.01B 45.11M 315M 125M 1.58B 119M 117M 4.98B	26.67M 29.87M 24.64M 22.33M 41.78M 2.84B 42.47M 297M 117M 1.49B 112M 110M 4.68B